Inactive Instrument

HEMK SWED Stock Nasdaq Stockholm

Equities

SE0009320278

Medical Equipment, Supplies & Distribution

Financials

Sales 2022 4.74M 436K 0 Sales 2023 3M 275K 0 Capitalization 8.18M 752K 0
Net income 2022 -14M -1.29M - Net income 2023 -12M -1.1M - EV / Sales 2022 0.7 x
Net cash position 2022 3.19M 293K 0 Net cash position 2023 3.07M 282K 0 EV / Sales 2023 1.7 x
P/E ratio 2022
-0.33 x
P/E ratio 2023
-1.04 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 7.12%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 40 11-12-31
Director of Finance/CFO 47 15-12-31
Members of the board TitleAgeSince
Founder 50 09-12-31
Founder 52 09-12-31
Director/Board Member 65 17-12-31
More insiders
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
More about the company